Open an account

Lucid Diagnostics

LUCD · NASDAQ

$0.3519−$0.0255 (−6.76%)TodayMarket closed ·
Prev close $0.3774

About LUCD

Lucid Diagnostics, Inc. is a commercial-stage medical diagnostics technology company. The company is headquartered in New York City, New York and currently employs 82 full-time employees. The company went IPO on 2021-10-14. The firm is focused on patients with gastroesophageal reflux disease (GERD), also known as chronic heartburn, acid reflux or simply reflux, that leads to esophageal precancer and cancer, specifically highly lethal esophageal adenocarcinoma (EAC). The Company’s products include EsoGuard and EsoCheck. EsoGuard is a bisulfite-converted next generation sequencing (NGS) DNA assay performed on surface esophageal cells collected with EsoCheck. EsoCheck is a noninvasive swallowable balloon capsule catheter device capable of sampling surface esophageal cells in office procedures. The company consists of a vitamin pill-sized rigid plastic capsule tethered to a thin silicone catheter from which a soft silicone balloon with textured ridges emerges to swab surface esophageal cells. The company is also developing EsoCure, is an Esophageal Ablation Device, which is a technology that allows a clinician to treat dysplastic BE.

Employees
82
Headquarters
New York City, New York
Listed
Oct 14, 2021
Sector
Health Care
Industry
Health Care Equipment & Supplies
Website
luciddx.com

LUCD key statistics

Market cap
71.52M
Price-earnings ratio
0.00
Dividend yield
—
Average volume
2.07M
Volume
6.33M
Open price
$0.3683
High today
$0.3747
Low today
$0.3033
52 Week high
$1.63
52 Week low
$0.3583

Lucid Diagnostics (LUCD) at a glance

As of Oct 20, 2026, Lucid Diagnostics (LUCD) shares are priced at $0.3519, giving the company a market cap of 71.52M and a price-to-earnings ratio of 0.00.

Today the stock has traded between $0.3033 and $0.3747. The current price is 16.0% above the day's low and 6.1% below its high.

Volume so far is 6.33M shares, above the average of 2.07M shares a day.

Over the past year Lucid Diagnostics has ranged from $0.3583 to $1.63, and now sits -1% of the way up that range.

Lucid Diagnostics met or beat analyst EPS estimates in 4 of the last 8 quarters. In Q2 FY26 it reported -$0.08 per share against an estimate of -$0.0697.

The average analyst price target is $4.08, 1059.4% above the current price, from 4 recent ratings.

Analyst ratings

Latest rating from each analyst over the past 12 months

100%of 4 analyst ratings say Buy
  • Buy100.0%
  • Hold0.0%
  • Sell0.0%
Price target · 7 analystsAvg $4.08
Low
$2.02
Now
$0.3519
High
$9.98

LUCD earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 4 of the last 8 quarters, by 13.8% on average.

  1. Q3 FY24: reported -$0.25 per share against an estimate of -$0.2244
  2. Q4 FY24: reported -$0.18 per share against an estimate of -$0.1938
  3. Q1 FY25: reported -$0.52 per share against an estimate of -$0.1614
  4. Q2 FY25: reported -$0.08 per share against an estimate of -$0.1234
  5. Q3 FY25: reported -$0.10 per share against an estimate of -$0.1124
  6. Q4 FY25: reported -$0.10 per share against an estimate of -$0.102
  7. Q1 FY26: reported -$0.17 per share against an estimate of -$0.0847
  8. Q2 FY26: reported -$0.08 per share against an estimate of -$0.0697

LUCD news

  • Press releasePRNewswire

    Lucid Diagnostics Advances Multiple EsoGuard® and EsoCheck® Payment, Billing and Coding Pathways

  • Priya Nigam

    Lucid Diagnostics Could Be 'High In The Queue' For Medicare Coverage Decision, Analyst Says

  • Press releasePRNewswire

    PAVmed Provides Business Update and Reports Second Quarter 2026 Financial Results

  • Lucid Diagnostics Q2 2026 Earnings Call: Complete Transcript

  • Press releasePRNewswire

    Lucid Diagnostics Provides Business Update and Reports Second Quarter 2026 Financial Results

  • Press releasePRNewswire

    Lucid Diagnostics Secures Commercial Coverage Policy Spanning Multiple Health Plans for its EsoGuard® Esophageal DNA Test

  • Press releasePRNewswire

    Lucid Diagnostics to Participate in Upcoming Investor Conferences

  • Press releasePRNewswire

    PAVmed to Hold Second Quarter 2026 Business Update Conference Call and Webcast on August 14, 2026

Similar companies

Companies in the same industry as Lucid Diagnostics

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.